Cardiovascular diseases (CVD) remain a leading cause of death worldwide, despite continuous efforts to expand our knowledge on the molecular mechanisms driving distinct CVD. Moreover, the heterogeneous nature of CVD requires the emergence of cardiovascular precision medicine as an alternative to current therapies with limited efficacy, especially with the ever-growing list of candidate genes derived from GWAS. Animal models that faithfully mirror human disease are a prerequisite to study the molecular mechanisms driving vascular and cardiac disorders and to expedite drug discovery. While murine models have proven invaluable over the last decades, they do not allow to simultaneously interrogate the function of multiple candidate genes, nor are they suitable for large-scale screens to identify disease modifiers at unprecedented rate. Our lab uses both in vitro (human ESC/iPSC) and in vivo (zebrafish) to model various cardiovascular disorders and integrates transcriptional, (epi)genetic, metabolic and phenotypic profiling at whole organism, tissue and single cell-level to fully understand the earliest molecular events characterizing disease onset, follow-up their dynamic changes over time and to identify disease biomarkers. Using fully automated microscopy, we furthermore conduct high-throughput screens to identify small molecule compounds that outperform current clinically used drugs. Our lab is currently looking for highly motivated post-doctoral candidates to join our dynamic, international team of PhD candidates, students, post-docs and medical professionals. Prior expertise in bio-informatics and/or zebrafish research is a favorable, but not required.